The investigation focused principally on two important hereditary syndromes: hereditary breast and ovarian cancer associated with germline pathogenic variants in BRCA1, and Lynch syndrome, which arises from inherited defects in DNA mismatch-repair genes. Germline variants are present in virtually every cell of the body, meaning that their biological effects can extend beyond the tissues in which tumors eventually develop. In BRCA1-associated disease, impaired repair of DNA double-strand breaks can increase genomic instability. Lynch syndrome, by contrast, is linked to faulty correction of replication errors, producing mismatch-repair deficiency and a high burden of mutations. Both settings can generate abnormal cells that immune surveillance mechanisms may recognize and eliminate before they progress into invasive cancer.

To investigate how these inherited risks intersect with immunity, the researchers combined three complementary technologies. Single-cell transcriptomics measured gene-expression programs in individual immune cells, allowing the team to distinguish subtle functional states that can be hidden when millions of cells are analyzed together. Multiparametric mass cytometry used metal-tagged antibodies and time-of-flight mass spectrometry to identify numerous proteins on and inside immune cells simultaneously, enabling detailed classification of lymphocyte and myeloid-cell populations. Cytokine profiling provided a biochemical readout of soluble immune signals circulating in blood. Together, these methods offered a multidimensional picture of immune-cell abundance, activation, differentiation, and communication in people with and without hereditary cancer risk.

One of the clearest observations was a reduction in the abundance of peripheral B cells in both women with BRCA1 germline pathogenic variants who had breast cancer and individuals with Lynch syndrome. The B-cell compartment also displayed a more differentiated phenotype. B cells are best known for producing antibodies, but they also present antigens to T cells, organize immune memory, and release regulatory molecules that influence inflammation. Their maturation proceeds through several stages, from naïve cells that have not yet encountered their target antigen to memory and antibody-secreting populations. A shift toward more differentiated states, together with lower overall abundance, may therefore reflect altered immune experience or regulation rather than a simple loss of immune function. The study does not show whether these changes are harmful, protective, or consequences of other biological processes.

The immune profile was especially notable among cancer-free women carrying BRCA1 pathogenic variants. Although these participants had no manifest cancer at the time of assessment, multiple immune-cell lineages showed an activated phenotype resembling that observed in patients with established disease. Activation can involve increased expression of antigen-presentation molecules, co-stimulatory proteins, inflammatory receptors, or cytotoxicity-associated markers. In practical terms, the result suggests that the immune system may be responding to persistent cellular stress, altered tissue signals, or the continual emergence and removal of abnormal cells in individuals with inherited susceptibility. This interpretation remains provisional: an activated peripheral immune profile is not equivalent to a tumor-specific response, and it should not be treated as evidence that cancer is present or imminent.

Lynch syndrome revealed a different pattern. In this group, B-cell phenotypes showed the largest changes associated with cancer eradication, indicating that the immune system’s circulating B-cell landscape may be particularly sensitive to the presence or removal of Lynch-associated tumors. The researchers also detected increased levels of interleukin-6, or IL-6, in presymptomatic individuals with Lynch syndrome. IL-6 is a multifunctional cytokine involved in acute and chronic inflammation, B-cell maturation, hematopoiesis, and communication between immune and nonimmune tissues. Persistently elevated IL-6 has been reported in several inflammatory and malignant conditions, but its presence in people without diagnosed cancer should be interpreted cautiously. The finding may reflect a syndrome-associated immune state, yet it requires validation in larger longitudinal cohorts before it can be considered a risk marker.

The contrast between the two syndromes is scientifically important because it argues against a single, universal immune signature of hereditary cancer predisposition. BRCA1 carriers appeared to show broad activation across several immune lineages even before disease became clinically evident, whereas Lynch syndrome was characterized more strongly by changes in B-cell states and systemic IL-6 elevation. These differences may arise from the distinct molecular defects underlying the syndromes, the tissues most vulnerable to transformation, the types of abnormal antigens generated, or the immune consequences of previous cancers and treatments. The study’s use of single-cell and high-dimensional protein measurements allowed the researchers to detect this biological complexity rather than reducing immunity to a single white-blood-cell count or inflammatory marker.

The findings also have potential implications for cancer interception, an emerging field focused on preventing malignancy or detecting it at its earliest stages. If immune alterations can be confirmed as stable, syndrome-specific, and predictive, they might eventually be used alongside genetic testing, imaging, endoscopic surveillance, and clinical history to refine individual risk assessments. They could also help identify biological pathways that are susceptible to intervention. The study points toward possible relevance for immune-checkpoint inhibitors, drugs that release inhibitory signals on T cells and are already important in mismatch-repair-deficient cancers. However, the researchers do not present evidence that immune therapy should be given to cancer-free carriers, and preventive treatment would require rigorous trials because immune activation can produce serious toxicity without providing benefit.

Several limitations place the results in context. The research captures immune features at one point in time, so it cannot determine how these profiles evolve before cancer, during tumor formation, after treatment, or over long-term surveillance. The participants also represent specific hereditary syndromes and clinical groups, meaning that the findings should not automatically be generalized to every inherited cancer-risk gene. Immune measurements can be influenced by age, sex, infection, medication, previous cancer, surgery, hormonal status, and other environmental factors. Even highly detailed molecular signatures may be difficult to translate into routine clinical testing unless they demonstrate reproducibility and clear predictive value. Future prospective studies following unaffected carriers over time will be essential to determine whether the observed immune states identify individuals at greater risk or instead reflect protective surveillance.

For now, the study provides evidence that hereditary cancer predisposition is accompanied by systemic immunological changes that can be detected in the bloodstream, including in people who appear clinically healthy. Its central message is not that an activated immune profile diagnoses cancer, but that inherited susceptibility and immune biology are closely connected. By mapping these connections across B cells, T cells, myeloid populations, and circulating cytokines, the researchers have created a foundation for investigating how the body recognizes and controls precancerous cells. The long-term goal is a more individualized approach to prevention—one that combines inherited genetic information with dynamic measurements of immune function to identify the most appropriate surveillance and risk-reduction strategies for each person.

Subject of Research: Systemic immune activation and peripheral immune alterations in hereditary cancer predisposition syndromes, particularly BRCA1-associated hereditary breast and ovarian cancer syndrome and Lynch syndrome.

Article Title: Systemic immune activation in hereditary cancer predisposition syndromes: a cross-sectional study

Article References: Kelemen, I., Horti-Oravecz, K., Bozsik, A. et al. “Systemic immune activation in hereditary cancer predisposition syndromes: a cross-sectional study.” BMC Medicine (2026).

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05188-x

Keywords: Hereditary breast and ovarian cancer syndrome, BRCA1, Lynch syndrome, precancer immunity, peripheral immune phenotype, cancer immunosurveillance, immune-checkpoint inhibitors, mass cytometry, single-cell transcriptomics, cytokine profiling

In current screening strategies, individuals are typically prioritized using age and non-genetic factors. But those approaches do not capture the substantial variation in inherited susceptibility. Polygenic scores offer a way to quantify this inherited component by aggregating the effects of thousands of variants, each contributing a small increase or decrease in likelihood of disease. When calibrated carefully, a GPS can stratify people into risk tiers more precisely than age alone.

The Danish team’s approach uses registry data—such as prior health history, demographic context, and family- or population-level signals available through longitudinal systems—alongside GPS. This hybrid framework aims to estimate an individual’s probability of developing colorectal cancer with greater fidelity. Technically, the model integrates genetic predictors and registry-derived covariates, enabling recalibration of screening eligibility and expected benefits at the population level.

Importantly, the study explores a risk-based screening lens rather than a one-size-fits-all schedule. In such schemes, people at higher predicted risk are potentially screened earlier or more intensively, while those at lower risk may safely defer. The authors frame this as a balance between cancer prevention and the downsides of over-screening, including unnecessary procedures and system costs.

The implications extend beyond screening logistics. If genetics-informed stratification improves sensitivity to future cases, health systems could detect tumors earlier and reduce the interval during which disease remains undetected. At the same time, improved targeting can make screening programs more sustainable by concentrating resources where the yield is highest.

As genetic risk scoring moves from research into clinical pipelines, studies like this highlight a key challenge: GPS performance depends on calibration, ancestry alignment, and careful validation. By embedding GPS within registry-based prediction, the authors suggest a pragmatic path to strengthen generalizability and decision relevance.

Ultimately, this study proposes a new standard for how risk prediction might be operationalized—turning genomic signals into actionable public health intelligence. If confirmed in larger, diverse cohorts, the genome-registry combination could reshape colorectal screening into a more precise, viral-speed upgrade of prevention strategies.

Subject of Research: Risk prediction for colorectal cancer to enable risk-based screening.

Article Title: Combining genome-wide polygenic scores with registry data for colorectal cancer risk-based screening.

Article References: Nøhr, A.K., Overby, M.G., Nielsen, M.M. et al. Combining genome-wide polygenic scores with registry data for colorectal cancer risk-based screening. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03532-9

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03532-9

Keywords:

Cancer patients who discover they carry pathogenic germline variants often grapple not only with the implications for their own health but also with the daunting responsibility of communicating these findings to relatives who might share their elevated risk. Traditional clinical workflows typically focus on the diagnosed patient, leaving relatives unmonitored and uninformed despite their potential susceptibility. This disjunction poses a critical public health lacuna: without effective outreach and counseling, families cannot make informed decisions about surveillance or preventive interventions, potentially missing the opportunity to avert future cancer cases.

The GIFT platform was meticulously engineered to bridge this communication divide by offering a comprehensive, web-based intervention. It combines educational modules elucidating the genetic underpinnings of cancer risk with decision support mechanisms that empower patients to comfortably share test results with family members. Beyond patient education, GIFT uniquely provides a secure portal through which patients can invite first- and second-degree relatives to engage with tailored content regarding their own genetic risk, alongside tools that guide them through the decision-making process about whether to pursue genetic testing.

To evaluate the efficacy of this intervention, a cluster randomized trial enrolled 414 cancer survivors diagnosed between 2018 and 2019, all confirmed carriers of pathogenic variants known to increase cancer risk. Participants were randomized across two variables: the mode of intervention delivery—online only versus facilitated by a human navigator—and the cost of genetic testing offered to relatives—either free or at a $50 fee. These parameters assessed not only the uptake of the platform but also the impact of human interaction and financial barriers on engagement rates.

The trial’s outcomes yielded insightful observations. Approximately 20% of patients utilized the platform to invite relatives, and among those relatives, roughly one-third enrolled in the program voluntarily. Strikingly, an overwhelming 90% of enrolled relatives proceeded to order genetic testing, underscoring the latent demand and readiness within families when appropriately supported. Contrary to expectations, the presence of a human navigator did not significantly augment enrollment or testing rates, affirming the potential sufficiency of a well-designed, self-directed online tool in facilitating cascade testing.

Cost analysis revealed a more nuanced dynamic. Relatives offered free genetic testing were twice as likely to complete testing compared to those facing a $50 fee, highlighting that financial incentives substantially influence testing uptake. Yet, despite the increase, overall testing numbers remained modest, pointing to persistent barriers beyond economic factors—possibly including psychological readiness or lack of awareness—that require further exploration and targeted strategies.

Steven J. Katz, M.D., M.P.H., the principal investigator and a prominent professor at the Rogel Cancer Center, emphasized the transformative promise of the GIFT platform. He noted that this web-based intervention could serve as a scalable and cost-efficient blueprint for integrating cascade genetic education and testing into routine oncology care. By empowering patients to take active roles in their family’s health communication, the tool fosters a proactive network effect that could ultimately reduce cancer incidence through early detection and prevention.

In parallel, complementary research published in JCO Oncology Practice investigated how cancer patients engage with clinicians and family members when discussing genetic test results. This study, involving nearly 1,800 women with breast, ovarian, or uterine cancer, shed light on the communication landscape surrounding hereditary cancer risk. While a significant majority engaged with genetic counselors and acknowledged encouragement to inform relatives, only a minority received concrete advice on how to navigate these sensitive conversations, and even fewer instances involved counselors directly liaising with family members. This gap highlights the “big unmet need” articulated by Allison Kurian, M.D., M.Sc., from Stanford University, and underscores the necessity of formalized family referral services within clinical practices.

Acknowledging these challenges, the research team is advancing a second-generation iteration of the GIFT platform, integrating an artificial intelligence (AI) assistant aimed at personalizing genetic risk information based on individual family dynamics and enhancing communication efficacy. By tailoring messages and resource recommendations, AI-driven customization promises to overcome psychological and informational barriers, fostering more meaningful and sustained family engagement.

Lawrence C. An, M.D., co-director of Rogel’s Center for Health Communications Research, underscored the user-friendly nature of the current GIFT platform. Participants reported ease of use and autonomy in navigating the educational materials and testing procedures without requiring assistance from human navigators. This intuitive design exemplifies how emerging digital communication technologies can effectively personalize patient outreach, break down longstanding bottlenecks in cascade testing, and ultimately narrow disparities in hereditary cancer risk management.

Looking ahead, the increasing adoption of germline genetic testing—projected to exceed 250,000 cancer patients yearly—magnifies the imperative to refine strategies for family engagement. As the compendium of recognized pathogenic variants, now encompassing over 40 cancer-associated genes, continues to expand, the healthcare system must equip itself with scalable, evidence-based tools like GIFT to ensure that genetic insights translate into actionable risk mitigation for entire families.

Successful cascade genetic testing not only clarifies individual and familial cancer risk landscapes but also empowers relatives to make informed decisions regarding enhanced surveillance or prophylactic interventions that could drastically alter disease trajectories. Although complex familial communication patterns and psychological factors present formidable barriers, digital interventions that are accessible, cost-effective, and patient-centered offer promising solutions.

The GIFT study represents a pioneering leap toward closing the loop in hereditary cancer risk management. By harnessing the confluence of genetic science, health communication, and digital technology, it paves the way for a future where inherited cancer risk is managed collaboratively within families, reducing preventable cancers and improving outcomes on a population scale.

Subject of Research: People

Article Title: Results From the Genetic Information and Family Testing (GIFT) Study: A Cluster Randomized Trial

News Publication Date: 24-Mar-2026

Web References:

• Journal of Clinical Oncology article
• Related study in JCO Oncology Practice

References:
“Results From the Genetic Information and Family Testing (GIFT) Study: A Cluster Randomized Trial,” Journal of Clinical Oncology. DOI: 10.1200/JCO-25-02196
“Patient Engagement with Clinicians and Family Members About Genetic Test Results Across Risk Groups in Women with Hereditary Cancer Susceptibility,” JCO Oncology Practice. DOI: 10.1200/OP-25-00776

Image Credits: Jacob Dwyer, Michigan Medicine

Keywords: Genetic testing, Genetic counseling, Cancer, Cancer genetics